Merck Unveils First-in-Human Data for PD-1/VEGF Bispecific MK-2010

Merck disclosed first-in-human clinical data for MK-2010, a PD-1/VEGF bispecific antibody, at AACR 2026, marking an early but important step for its next-generation oncology pipeline. The data support the program’s biological rationale and keep it in the race versus competing PD-1/VEGF bispecifics such as ivonescimab, though Phase 1 results remain preliminary. The readout is strategically positive for Merck as pembrolizumab faces biosimilar pressure later this decade.

Analysis

The market is likely underappreciating how strategically important a credible PD-1/VEGF bispecific is for Merck’s long-duration oncology franchise. If MK-2010 shows even mid-pack differentiation on tolerability and early activity, it gives Merck a path to defend immuno-oncology share without relying on a weakening single-mechanism backbone; that matters more than the near-term clinical readout because it shifts the conversation from Keytruda saturation to platform continuity. The second-order effect is competitive pressure on any company selling “next-gen IO” as a pure checkpoint story: the bar is now combination biology plus manufacturing scalability, not just incremental PD-1 optimization.

The bigger read-through is to SMMT. Summit’s bull case improves if the market increasingly treats PD-1/VEGF as a validated class rather than a one-off China signal, because Merck moving into the same lane reduces the perception that ivonescimab is a niche regional anomaly. But that also creates a future pricing and data-risk overhang: once a U.S. large-cap validates the mechanism, investors will focus on which asset has cleaner dosing, fewer VEGF-related toxicities, and better global development execution. That favors the best-tolerated, most operationally flexible program rather than the first mover.

Contrarian risk: this is still an early-phase derisking event, not proof of commercial displacement. The market may be extrapolating a class win too quickly; many bispecifics fail on exposure control, immune toxicity, or dose intensity long before registrational data. Near term, the main catalyst is not efficacy headlines but whether Merck gives a fast follow on expansion cohorts or indication prioritization within the next 3-6 months; failure to do so would suggest the signal is weaker than the headline implies.

Key Decisions for Investors

• Long SMMT on a 1-3 month horizon as a momentum/relative-value expression of PD-1/VEGF class validation; target 15-25% upside if the market starts pricing ivonescimab as a platform winner, but use a tight 10-12% stop because Merck’s entry can compress the scarcity premium.
• Pair trade: long SMMT / short MRK into the next 4-8 weeks of biotech data flow; this isolates mechanism validation while hedging broad large-cap pharma beta. Best if Merck’s follow-up data are incremental rather than clearly superior.
• If options liquidity is adequate, buy SMMT call spreads 2-4 months out to capture re-rating while capping premium paid; this is attractive if implied vol stays below realized event vol, with asymmetric payoff into any class-wide enthusiasm.
• Avoid chasing MRK on this headline alone; treat MK-2010 as a long-dated pipeline call, not a near-term earnings driver. Reassess only if Merck announces accelerated indication prioritization or out-of-cycle expansion data within 6 months.
• Watch for a reversal signal in SMMT if Merck’s program shows materially better tolerability or broader tumor applicability in subsequent cohorts; that would shift the trade from class-validation long to competitive-share concern and justify trimming 30-50% of exposure.